Parabilis Medicines, Inc.
PBLS
$38.76
-$1.01-2.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 30.71% | -- | |||
| Gross Profit | -30.22% | -- | |||
| SG&A Expenses | 118.42% | 83.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 43.91% | 21.10% | |||
| Operating Income | -43.49% | -21.10% | |||
| Income Before Tax | -50.71% | -18.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -50.71% | -18.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -50.71% | -18.24% | |||
| EBIT | -43.49% | -21.10% | |||
| EBITDA | -44.33% | -21.59% | |||
| EPS Basic | 89.61% | -45.01% | |||
| Normalized Basic EPS | 89.47% | -16.37% | |||
| EPS Diluted | 89.61% | -45.01% | |||
| Normalized Diluted EPS | 89.47% | -16.37% | |||
| Average Basic Shares Outstanding | 1,331.74% | 1.61% | |||
| Average Diluted Shares Outstanding | 1,331.74% | 1.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||